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Abstract
Chronic obstructive pulmonary disease (COPD) affects approximately 10% of adults older than 40 years and is an important 
causes of disability and death in elderly subjects. A large proportion of COPD patients suffer from cardiovascular comorbidities. 
Thromboembolic events contribute considerably to morbidity and mortality in these subjects. This review summarizes the current 
evidence regarding the association of COPD with increased thromboembolic risk. We discuss multiple mechanisms potentially 
linking these conditions and available pharmacological interventions reducing the risk of thrombotic arterial and venous events 
with special attention paid to new oral anticoagulants. 
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Introduction
Chronic obstructive pulmonary disease 
(COPD) is one of the most common chronic dis-
orders in adults. The prevalence of the clinically 
overt COPD in subjects aged 40 years or more is 
estimated at about 10% [1]. Furthermore, COPD 
prevalence is likely to rise because of aging of 
the Western societies and common exposure to 
tobacco smoke in the past those currently aged 
over 50 years. 
The disease has substantial burden, evi-
denced both by direct influence on the affected 
individuals and socio-economic consequences on 
societies. In the European Union, COPD accounts 
for more than a half of health care expenditures 
on respiratory system diseases [2]. COPD is the 
third leading cause of death in the United States, 
and according to the World Health Organization 
prognosis until 2030, it will become the third 
leading cause of death also globally [3].
Knowledge on COPD evolved towards grow-
ing recognition of a systemic component of the 
disease and a  role of its comorbidities. This is 
reflected by changes in the Global Initiative for 
Obstructive Lung Disease (GOLD) definition, 
which since 2006 has mentioned ‘significant 
extrapulmonary effects’ of COPD [4], and re-
cently (since 2011) included the statement that 
‘comorbidities contribute to overall severity in 
individual patients’ [2]. Cardiovascular diseases 
(CVDs) are the leading comorbidities in COPD 
and are responsible for a considerable proportion 
of hospitalizations and deaths in COPD subjects 
[4]. CVDs co-existing with COPD include venous 
thromboembolism (VTE), ischemic heart disease, 
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stroke, cardiac arrhythmias and heart failure. 
Epidemiological data indicate that CVDs occur 
more commonly in COPD subjects compared to 
controls without this disease. This association at 
least partially results from common risk factors, 
especially tobacco smoking, but there are data 
suggesting that COPD (or reduced lung func-
tion) represents an independent risk factor for 
CVDs. There is also a growing body of evidence 
documenting a prothrombotic state in COPD. 
This review summarizes the current evidence 
on increased thromboembolic risk in COPD and 
discusses potential mechanisms behind this link. 
We also provide data on established and new 
methods of pharmacological thromboprophylaxis. 
COPD and cardiovascular risk: epidemiological 
data
Data from large clinical trials indicate that 
CVDs are among the most common causes of 
death in COPD subjects [5–7]. Observational 
studies have compellingly shown that diagno-
sis of COPD increases the risk of CVDs. This 
association was strongly supported by studies 
performed in a cohort of the Kaiser Permanente 
Medical Care Program recipients [8], a combined 
database from the Atherosclerosis Risk in Com-
munities Study (ARIC), and the Cardiovascular 
Health Study (CHS) [9]. The Veterans Adminis-
tration Medical System data demonstrated a sig-
nificant association of COPD with an increased 
risk of coronary artery disease, heart failure and 
atrial fibrillation (AF) [10]. Common risk fac-
tors of COPD and CVDs necessitate caution in 
interpreting the results of observational studies, 
and indeed not in all of the published studies 
association of COPD diagnosis with increased 
CVDs risk was independent [11]. There is also 
a possibility that not COPD itself, but rather 
a  reduction in lung function is responsible for 
the increased risk of CVDs. This hypothesis is 
supported by the studies demonstrating that 
both obstructive and restrictive patterns of lung 
function impairment are related to this increased 
risk [12]. On the other side, also subjects with 
normal lung function, but with symptoms of 
chronic bronchitis (chronic cough and sputum 
production) probably have increased CVDs risk. 
For example, chronic bronchitis symptoms were 
associated with increased risk of ischemic heart 
disease and ischemic heart disease-related death 
in a 13-year follow-up of a large Finnish cohort 
[13]. Furthermore, excessive FEV1 decline, which 
is a lung function variable related to disease ac-
tivity in COPD, was also reported to be associated 
with increased risk of CVDs [14] and ischemic 
heart disease-related death [15]. 
Importantly, COPD worsens outcomes in 
subjects with confirmed ischemic heart disease. 
Such observations were reported for example in 
a prospectively followed cohort of patients after 
percutaneous coronary interventions [16] or in 
a retrospective study performed in patients after 
myocardial infarction [17]. In a  recently pub-
lished analysis of a large Swedish registry, COPD 
was likewise related to increased risk of death 
after myocardial infarction (crude rates: 24.6% 
vs. 13.8%, multivariate analysis: HR 1.14, 95% CI: 
1.07 to 1.21) [18]. However, this study provided 
another interesting observation — similarly to 
other data, association of COPD with increased 
mortality was attenuated after adjustment for 
known confounders. The investigators also found 
that COPD patients less often received effective 
treatment, including thrombolysis, anticoagula-
tion or b-blockers [18]. 
Of note, COPD is related to increased risk of 
AF as evidenced by several observational studies 
[8, 10]. Long-term follow-up data from large co-
horts (Copenhagen Heart Study [19], ARIC Study 
[20]) have also revealed increased risk of AF in 
individuals with reduced lung function. Some 
of the drugs commonly used in COPD (b2-ago-
nists and theophylline) are known to increase 
the occurrence of AF. In a  large registry of AF 
subjects, the presence of COPD correlated with 
worse prognosis (risk of death 26.9% vs. 12.3%; 
HR 1.49, p < 0.05), yet the prevalence of stroke 
was similar regardless of the lung disease [21]. Re-
cently, COPD has been demonstrated to represent 
an independent predictor of mortality in a large 
registry of the European AF subjects [22]. AF in 
COPD subjects is also recognized as a negative 
prognostic factor in the context of exacerbations 
with hypoxia, as suggested in the European Heart 
Rhythm Association/European Association of Car-
dio-Thoracic Surgery Guidelines [23]. Association 
of reduced lung function/COPD with increased 
risk of stroke was reported in the Copenhagen 
Heart Study [24] and the British Regional Heart 
Study [25]. In a study on large series of stroke 
subjects COPD was identified as an ischemic 
stroke risk factor [26].
Exacerbations of COPD pose direct threat to 
patients’ life, have negative impact on patients’ 
quality of life and accelerate lung function decline 
[2]. Thromboembolic events often impact the 
prognosis during exacerbations of COPD which 
has been reported to increase the risk of both 
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myocardial infarction and stroke [27]. Venous 
thromboembolism (VTE) is also a common threat 
to hospitalized COPD patients. In a meta-analysis, 
pulmonary embolism prevalence was estimated 
to affect 20% of subjects with COPD exacerbation 
(25% in hospitalized patients, and 3.3% of those 
treated in the emergency department), whereas 
deep vein thrombosis was detected in 12.4% of 
those patients [28]. COPD is associated with in-
creased venous thromboembolic risk as shown in 
a number of epidemiological studies, including 
the Kaiser Permanente Medical Care Program data 
[8] and the General Practice Research Database 
[29]. VTE in COPD more often manifests as pul-
monary embolism with increased risk of death as 
compared to individuals who do not suffer from 
COPD [30].
Potential mechanisms
There are several mechanisms that may link 
COPD with increased risk of thromboembolic 
complications: 1) systemic inflammation, 2) 
hypoxemia and enhanced oxidative stress, 3) 
endothelial dysfunction and 4) a prothrombotic 
state including platelet hyperreactivity, and 
augmented thrombin generation, in part associ-
ated with inflammatory state [4, 31]. Prolonged 
low-grade systemic inflammation in COPD is 
evidenced by increased serum concentrations of 
inflammatory markers such as C-reactive protein 
(CRP), fibrinogen, interleukin 6, interleukin 8 and 
tumor necrosis factor a [32]. Exacerbations, which 
are important events in the course of COPD, can 
lead to further elevation in systemic inflammation 
[33]. Low grade inflammation is a well-known risk 
factor for coronary heart disease [34] and CRP 
concentration is associated with increased risk 
of cardiovascular events and death [35] in COPD. 
The inflammatory process can influence coagu-
lation in multiple ways. Some indirect evidence 
comes from in vitro studies. CRP may increase 
plasminogen activator inhibitor 1 activity [36] 
and decrease tissue plasminogen activator activity 
[37] and prostacyclin release [38] by endothelial 
cells. Ex vivo studies have identified multiple co-
agulation abnormalities in COPD. A study done in 
stable COPD subjects demonstrated higher rates 
of thrombin generation and formation as well as 
alterations in multiple plasma coagulation factors 
[39]. COPD subjects had a prominently elevated 
level of factor VIII, increased levels of prothrom-
bin, factor V, VII, IX, but reduced concentration 
of tissue factor pathway inhibitor. Interesting-
ly, these changes were observed irrespectively 
from the severity of COPD or concentrations of 
CRP and IL-6 [39]. The presence of circulating 
active tissue factor (TF) and activated factor XI 
(FXIa) was detected in a significant proportion 
(> 10%) of stable COPD patients, indicating 
ongoing activation of the extrinsic coagulation 
pathway driven by exposure of TF [40]. In that 
study, COPD patients with detectable active TF 
and FXIa had significantly higher CRP, fibrino-
gen and prothrombin fragment 1 + 2 (F1 + 2) 
levels, a marker of thrombin generation, which 
suggests a close link of hypercoagulability with 
inflammation in this disease. Similar findings 
were described in patients with coronary artery 
disease, especially those with acute coronary 
syndrome [41]. Increased procoagulant activity 
of TF in COPD was also confirmed in another 
study [42]. Another abnormality identified in 
COPD were unfavorable alterations to plasma 
fibrin clot structure and function, involving the 
formation of denser networks, more resistant 
to lysis, as compared to well-matched controls 
[43]. Interestingly, elevated CRP was a  strong 
and independent predictor of clot parameters in 
COPD, with improvement of these abnormalities 
following statin therapy despite negligible effects 
on CRP concentrations [43]. Similar changes were 
observed in stable ischemic heart disease [44]. 
Several studies documented increased plasma 
concentrations of markers of thrombin forma-
tion and/or activity (thrombin-antithrombin III 
complexes, fibrinopeptide A, F1 + 2) in COPD 
[45–50]. Of note, hypoxemic challenge caused an 
increase in thrombin-antithrombin III complexes 
and F1 + 2 in subjects with COPD [46].
Several investigators have suggested that 
low-grade inflammation in COPD largely con-
tributes to a prothrombotic state. Inflammation 
may act through increased platelet activity, as 
demonstrated by the correlation of CRP and IL-6 
concentrations with immature platelet counts in 
patients with stable ischemic heart disease [47] 
or with increased platelet derived inflammato-
ry transcripts in the Framingham Heart Study 
Offspring cohort data [48]. Increased circulating 
platelet-monocyte aggregates, a well-established 
marker of platelet activation, were demonstrat-
ed in subjects with both stable and exacerbated 
COPD [49]. It was suggested that low grade in-
flammation can cause thromboxane dependent 
platelet activation [50]. In stable COPD patients 
urinary levels of stable thromboxane metabolite 
(11-dehydro-TXB2) were elevated, correlated with 
partial arterial oxygen pressure and improved 
after short-term oxygen treatment [51]. b-throm-
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boglobulin, a specific marker of platelet activa-
tion, was elevated in some, but not all studies in 
COPD [45, 52], and increased platelet count was 
associated with increased mortality in patients 
following COPD exacerbation [53].
Reduced levels of vascular progenitor cells 
were reported in stable COPD [54] and it was sug-
gested as a potential mechanism of increased CVD 
risk (via reduced vascular repair capacity) [55]. 
Systemic inflammation is associated with 
increased AF prevalence and with decreased 
chance to restore sinus rhythm [56]. In one 
randomized trial methylprednisolone treatment 
significantly decreased the risk of AF recurrence 
[57]. In the ARIC study, increased levels of factor 
VIII coagulant activity, fibrinogen and vWf were 
associated with a higher mortality risk in subjects 
both with and without AF, while the higher level 
of protein C — with lower risk of ischemic stroke 
[58]. Systemic inflammation potentially can also 
influence the AF risk by affecting cardiac function 
in COPD subjects [59].
Management of COPD and thromboembolic risk
VTE in hospitalized COPD patients
The risk of VTE in hospitalized COPD pa-
tients is increased, inter alia, due to bedrest, 
advanced age and concomitant diseases. This 
risk in hospitalized subjects can be assessed with 
the Padua Prediction Score, a  tool validated in 
acutely ill medical patients (Table 1) [60]. VTE 
risk in those with “high-risk” score (≥ 4 points) 
who had not received prophylaxis was estimated 
at 11%, whereas in those with low risk it was 
only 0.3%. A study done exclusively in hospi-
talized COPD patients provided evidence that 
a history of malignancy and previous episodes 
of VTE (included in the Padua Score) increase 
pulmonary embolism risk in this population [61]. 
A majority of patients hospitalized due to severity 
of COPD exacerbation will have increased risk of 
VTE, and also according to the GOLD guidelines 
they should receive thromboprophylaxis [2]. 
The ACCP Guidelines advocates low molecular 
weight heparin, low-dose unfractionated heparin 
or fondaparinux in these patients [62]. In those 
with high bleeding risk mechanical prophylaxis, 
first of all compression stockings, should be used. 
Randomized trials addressing the effective-
ness of heparin prophylaxis solely in COPD are 
sparse. A study done in subjects mechanically 
ventilated due to COPD exacerbation confirmed 
effectiveness of low molecular weight heparin in 
reducing VTE risk, yet without documented gain 
Table 1.  VTE risk assessment using the Padua Risk Sco-
re (adapted from [55])
Item Points/risk 
Cancer (metastases and/or chemio- or 
radiotherapy in the previous 6 months 
3
Previous VTE (with the exclusion of su-
perficial vein thrombosis)
3
Bedrest (with bathroom privileges) for 
≥ 3 days 
3
Thrombophilia 3
Recent (≤ 1 months) trauma or surgery 2
Age ≥ 70 years 1
Heart and/or respiratory failure 1
Acute myocardial infarction or  
ischemic stroke 
1
Acute infection and/or rheumatologic 
disorder 
1
BMI ≥ 30 kg/m2 1
Ongoing hormonal treatment 1
≥ 4 points suggesting 
a high risk of VTE
VTE — venous thromboembolism; BMI — body mass index
in survival [63]. Evidence indicates that COPD 
patients should receive thromboprophylaxis like 
other medical hospitalized patients if their risk 
of VTE is increased unless there are contraindi-
cations e.g. active bleeding.
Unarguably, all hospitalized COPD subjects 
should be screened for signs and symptoms of 
deep vein thrombosis/pulmonary embolism. Risk 
of pulmonary embolism in COPD subjects pre-
senting to emergency department with pulmonary 
exacerbations was 6.2% in those with clinical 
suspicion vs. 1.3% in those without. Diagnostic 
performance of D-dimer as well as spiral com-
puted tomography in the diagnostic work-up of 
pulmonary embolism is not influenced by COPD 
exacerbation [64]. 
There is no data to support thromboprophy-
laxis in stable COPD subjects outside specific 
indications. The 2012 ACCP guidelines recom-
mend against routine use of thromboprophylaxis 
in chronically immobilized patients residing at 
home, which refers also to subjects with advanced 
COPD. Despite in the most severe COPD patients 
additional risk factors such as steroid therapy or 
respiratory insufficiency may further increase 
VTE risk, clinical trial assessing low molecular 
weight heparin in stable, severe COPD subjects on 
long term oxygen therapy has not demonstrated 
survival benefit, however it was underpowered 
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and had low quality [65]. Taken together, decision 
on thromboprohylaxis at home should be taken 
on an individual basis. 
The decision on the type of prophylaxis used 
in acutely ill subjects (pharmacotherapy vs. me-
chanical methods) is mostly based on the bleeding 
risk assessment. Multiple risk factors of in-hospi-
tal bleeding were identified: gastrointestinal ulcer, 
low platelet count, bleeding history, advanced age 
(≥ 85 years), hepatic or renal failure, rheumatic 
disease or cancer) [62]. Of those, active gastroduo-
denal ulcer, prior bleeding and low platelet count 
are the strongest predictors of bleeding [66]. Ad-
vanced age, which refers to most COPD subjects, 
also increases bleeding risk while on heparin. 
Systemic steroid therapy often used in COPD 
exacerbations is another factor that elevates the 
risk of gastrointestinal bleeding. The 2012 ACCP 
guidelines advocate to consider patients to have 
increased bleeding risk if they have one of the 
above mentioned factors with strong influence 
on bleeding risk or multiple risk factors and rec-
ommend against routine use of pharmacologic 
prophylaxis in those subjects. Available means 
of prophylaxis in patients with high bleeding 
risk comprise graduated compression stockings 
or intermittent pneumatic compression. 
Oral anticoagulants in COPD
The most common indication for long-term 
oral anticoagulation in COPD is co-existent AF. 
Anticoagulation is generally recommended in 
those with intermediate or high risk of stroke 
defined as at least 1 point in the CHA2DS2-VASc 
score (Table 2) [67].
COPD subjects with AF (paroxysmal, per-
sistent or permanent) due to frequent other 
comorbidities and/or advanced age usually fall 
into the high-risk category. In a  large registry 
of AF subjects, those with COPD significantly 
more often had CHA2DS2-VASc score ≥ 2 (81% 
vs. 65%) [21]. Both, vitamin K antagonists (VKA) 
and non-vitamin K oral anticoagulants or novel 
oral anticoagulants (NOACs) effectively reduce 
the risk of ischemic stroke and systemic throm-
boembolism by about 80%, as compared to up 
to 30% reduction on aspirin alone [68]. The 
VKA use requires regular laboratory control of 
anticoagulant effect and thoughtful avoiding of 
dietary changes and numerous drug interactions, 
which is often challenging, especially during 
COPD exacerbations. Multiple drugs, including 
commonly used antibiotics (macrolides [in par-
ticular clarithromycin], tetracyclines, cefuroxime, 
Table 2.  CHA2DS2-VASc scoring system in the assess-
ment of thromboembolic risk in AF subjects 
(adapted from [81])
Item Points
Congestive heart failure/left ventricular dysfunction 1
Hypertension 2
Age ≥ 75 years 2
Diabetes 1
Prior stroke or transient ischemic attack or systemic 
embolism 
2
Vascular disease (prior myocardial infarction, peri-
pheral artery disease or aortic plaque)
1
Age 64–74 years 1
Female sex 1
0 point — very low risk, 1 point — moderate risk, ≥ 2 points — high risk
cefoperazone, fluorochinolones, metronidazole, 
trimethoprim/sulfamethoxazole) influence VKA 
metabolism, leading to elevation of INR above 
3–4, especially if the therapy lasts more than 
5–7 days together with reduced vitamin K intake 
[69, 70]. Thus, NOACs may constitute a preferred 
alternative to VKA in these subjects, especially 
given the current recommendation to choose this 
option in Europe. 
NOACs currently available in Europe com-
prise dabigatran (thrombin inhibitor), apixaban 
and rivaroxaban (activated FX inhibitors). These 
drugs were directly compared to VKA in a  few 
large randomized clinical trials in non-valvular 
AF patients, including the open-label RE-LY Study 
[71], the ARISTOTLE Study aimed to compare 
apixaban and warfarin [72] and the ROCKET AF 
trial [73]. Similar results were published for edox-
aban, a NOAC which was approved in Europe 
in January 2015 [74]. These large clinical trials 
provided strong evidence for NOACs effectiveness 
and safety; they are non-inferior to warfarin. 
No specific studies compared NOACs with 
VKA in COPD subjects, yet a  significant num-
ber of COPD subjects participated in the above 
mentioned trials [71–74]. This proportion was 
about 10%, based on the published reports from 
the ROCKET-AF Trial (11% of all participants) 
[85] and the ARISTOTLE trial (9% of those with 
previous stroke or transient ischemic attack) [75]. 
The European Society of Cardiology guidelines 
consider NOACs as the preferred option to VKA 
in non-valvular AF, especially when starting anti-
coagulation in previously untreated subjects or in 
those who experienced thromboembolism while 
on VKA [23]. Switching patients with optimal 
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anticoagulation on VKA to NOACs is not justified, 
also in COPD patients free of bleeding tendency. 
Potential advantages of NOACs over VKA [76] 
may be particularly relevant in COPD subjects. 
NOACs are used in fixed doses without need for 
monitoring the pharmacological effect and are 
more convenient when anticoagulation is to be 
stopped or modified [77]. These situations com-
prise the need for surgery/invasive procedure. 
When bleeding risk is high, stopping the drug 
for ≥ 4 half-life time (usually 2–3 days — Table 
3) is recommended before the elective procedure 
[78]. When assessment of NOACs anticoagulation 
effect is necessary, routine coagulation tests are 
less informative than prothrombin time in case 
of VKA treatment. Factor Xa inhibitors, especially 
rivaroxaban, do prolong prothrombin time, yet 
this effect is variable and probably useful clini-
cally only for qualitative assessment of rivarox-
aban’s effect [78]. APTT provides only imprecise 
qualitative assessment of dabigatran’s  effect. 
Rivaroxaban and apixaban need anti-Xa assay for 
quantitative assessment. The effect of apixaban 
can be qualitatively evaluated with modified PT, 
while dabigatran — with dilute thrombin time or 
anti-factor II assay. When necessary and feasible, 
concentration of NOACs can be directly measured 
in plasma [79, 80].
NOACs differ in pharmacological characteris-
tics (Table 3), which may have important clinical 
consequences. Impaired renal function may need 
dose reduction or is a contraindication if chronic 
disease is in stage 4 or 5 [81]. These factors should 
be considered when treating COPD subjects, often 
encumbered with multiple comorbidities.
NOACs generally do not interact with an-
tibiotics, except rifampicin, erythromycin and 
clarithromycin [81]. Both clarithromycin and 
erythromycin interact with rivaroxaban and 
dabigatran, increasing NOAC’s effect by approx-
imately 20–50%, while rifampicin decreases the 
effect of rivaroxaban and increases the one of 
dabigatran and apixaban [78]. Some other drug 
interactions of NOACs include amiodarone, 
verapamil, diltiazem, azole antimycotics, cyclo-
sporine, tacrolimus, HIV protease inhibitors and 
carbamazepine [82]. Of those interactions with 
antiarrhythmics, the most important for COPD 
Table 3. Pharmacological properties of NOACs (reprinted with permission [76])
Warfarin Dabigatran etexilatea Rivaroxaban Apixaban
Mode of action ↓synthesis of vitamin 
K-dependent coagulation 
factors
Direct selective and re-
versible thrombin inhibitor
Direct selective and re-
versible activated factor 
X inhibitor
Direct selective and re-
versible activated factor 
X inhibitor
Time to peak plasma con-
centration
90 min (peak action after 
4–5 d)
0.5–2 h 2–4 h 1–4 h
Half-life 36–42 h 12–14 h 5–9 h (young)
–13 h (age > 65 years)
8–13 h
Substrate of P-glycopro-
tein transporter
No Yes Yes Yes 
Substrate of CYP en-
zymes 
Yes (CYP3A4, CYP2C9) No Yes (CYP3A4/5, CYP2J2) Yes (CYP3A4, CYP2C9)
Route of elimination Variousb 80% renal 66% renal (33% unchan-
ged)
25% renal
Protein binding 99% 35% 90% 90%
Basic daily dose in AF ~5 mg (1–18 mg) target 
INR 2–3
2 × 150 mg 1 × 20 mg 2 × 5 mg
Reduced daily dose               Not applicable 2 × 110 mgc 1 × 15 mg 2 × 2.5 mg
Indications for reduced 
dosage
Not applicable — creatinine clearance 
30–49 mL/min
— HAS-BLED ≥ 3 points
— age ≥ 80 years
— co-administration of 
verapamil
— creatinine clearance 
30–49 mL/min
— HAS-BLED ≥ 3 points
— creatinine ≥ 133 µM
— age ≥ 80 years
— body weight ≤ 60 kg 
(2 or 3 criteria MET)
aA prodrug that undergoes biotransformation to the active molecule, dabigatran, by esterases; bThe anticoagulant effect of warfarin is eliminated through synthesis 
of functionally active coagulation factors rather than through elimination of warfarin; coagulation factor synthesis is hastened by exogenous vitamin K; cIn the United 
States: 2 × 75 mg daily (2 × 110 mg not approved)
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subjects are verapamil and amiodarone that 
increase dabigatran’s effect and diltiazem that 
increases apixaban’s effect.
Bleeding complications are the major threat 
for both, patients on anticoagulation and their 
physicians. Assessment of the bleeding risk 
with the validated HAS-BLED scale is helpful in 
managing subjects with AF (Table 4). The risk of 
bleeding increases with age, which is important 
as most of COPD subjects are in advanced age 
[83]. COPD patients often have poor adherence 
to treatment [84] and those treated with VKA 
should be supervised thoroughly, as poor control 
of therapy is another risk factor for bleeding [85]. 
Most experts consider NOACs as a safer thera-
peutic option in COPD patients compared with 
VKA. Large trials comparing NOACs with VKA 
identified multiple risk factors associated with 
increased bleeding risk. Of note, in a ROCKET 
AF trial history of COPD was one of bleeding risk 
factors [86]. Other risk factors independently as-
sociated with major bleeding risk included older 
age, baseline diastolic blood pressure (DBP) ≥ 90 
mm Hg, gastrointestinal bleeding, prior acetylsal-
icylic acid use, and anemia; female sex and DBP 
< 90 mm Hg were associated with a decreased 
risk. Analysis of the ARISTOTLE trial data with 
apixaban identified older age, prior hemorrhage, 
prior stroke or transient ischemic attack, diabetes, 
low creatinine clearance, decreased hematocrit, 
use of acetylsalicylic acid or other nonsteroidal 
anti-inflammatory drugs as risk factors for bleed-
ing, COPD was not a risk factor [87]. Subjects 
with COPD, usually presenting with multiple 
comorbidities, often have increased bleeding risk.
Antiplatelet drugs in COPD
Antiplatelet therapy reduces cardiovascular 
risk in the prevention and treatment of athero-
thrombotic events [88]. Indications for anti-
platelet therapy are not different in COPD when 
compared to subjects with normal lung function, 
yet there are some data, indicating that COPD sub-
jects are less likely to receive proper treatment. 
A study based on Krakow Registry of Acute Coro-
nary Syndromes data reported that patients with 
COPD less often received antiplatelet therapy (as-
pirin and clopidogrel) during hospital stay [89]. 
Furthermore, they have higher risk of in-hospital 
death, and multivariate analysis confirmed COPD 
diagnosis as an independent predictor of in-hos-
pital death. A recently published observational 
study identified association of aspirin use with 
improved survival after COPD exacerbation [53] 
and it was suggested that routine use of low dose 
Table 4.  HAS-BLED score to assess bleeding risk in pa-
tients with atrial fibrillation (adapted from [81])
Item Points/risk
Hypertension (systolic pressure > 160 mm Hg) 1
Abnormal renal function 1
Abnormal liver function 1
Age ≥ 65 years 1
Prior stroke 1
Prior bleeding 1
Labile INRs (e.g. time in therapeutic range < 60%) 1
Taking other drugs at the same time (e.g. ASA, 
NSAIDs) 
1
Alcohol intake 1
≥ 3 points 
means 
a high risk of 
bleeding
INR — international normalized ratio; ASA — acetylsalicylic acid; NSAIDs — 
nonsteroidal anti-inflammatory drugs
aspirin should be considered after COPD exacer-
bations [90]. 
Conclusions
A large body of epidemiological data supports 
hypothesis that COPD increases venous and ar-
terial thromboembolic risk. Diverse coagulation 
abnormalities were identified in the COPD ranging 
from those associated with systemic inflammation 
and hypoxemia to a hypercoagulable state. Further 
studies are needed to fully elucidate these mecha-
nisms. Unarguably, in every COPD patient empha-
sis should be placed on thromboprophylaxis when 
necessary and CVDs should be searched for with 
implementation of effective pharmacotherapy, 
once the diagnosis is established. New therapeu-
tic modalities have the opportunity to improve 
outcomes and possibly prolong patients’ lives.
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